Diabetes modulates the expression of glomerular kinin receptors

International Immunopharmacology

Volumn 2, Issue 13-14, 2002, Pages 1771-1779

  Christopher, Julie ^a   Jaffa, Ayad A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

B1 receptors; B2 receptors; Diabetes; Glomerulosclerosis; Glucose; MAPK

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; BRADYKININ[1-8]; GLUCOSE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; STREPTOZOCIN; BRADYKININ; BRADYKININ RECEPTOR; BRADYKININ, DES ARG(9); BRADYKININ, DES-ARG(9)-; DRUG DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME PHOSPHORYLATION; GLOMERULUS; GLUCOSE BLOOD LEVEL; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; MESANGIUM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BRADYKININ; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATION; GLOMERULAR MESANGIUM; GLUCOSE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; SIGNAL TRANSDUCTION;

EID: 0036891715     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00188-1     Document Type: Article

References (27)

1. Klahr S., Schreiner G., Ichikawa I. The progression of renal disease. N. Engl. J. Med. 318:1988;1657-1666.
2. United States Renal Data System (USRDS), 2000 Annual Data Report. National Institutes of Health, Bethesda, MD.
3. Mauer M., Drummond K. The early natural history of nephropathy in type 1 diabetes: study design and baseline characteristics of the study participants. Diabetes. 51:2000;1572-1579.
4. Drummond K., Mauer M. The early natural history of nephropathy in type 1 diabetes: early renal structural changes in type 1 diabetes. Diabetes. 51:2002;1580-1587.
5. Wolf G., Ziyadeh F.N. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. 56:1999;393-405.
6. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int. 47:1995;1703-1720.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 414:2001;813-820.
8. DeRubertis F.R., Craven P.A. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms of potential links to the pathogenesis of diabetic glomerulopathy. Diabetes. 43:1994;1-8.
9. Koya D., Jirousek M.R., Lin Y.W., Ishii H., Kuboki K., King G.L. Characterization of PKCbeta isoform activation on gene expression of transforming growth factor beta, extracellular matrix components and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. 100:1997;115-126.
10. Harvey J.N., Edmundson A.W., Jaffa A.A., Martin L.L., Mayfield R.K. Renal kallikrein excretion of kallikrein and eicosanoids in patients with type 1 diabetes: relationship to glomerular and tubular function. Diabetologia. 35:1992;857-862.
11. Harvey J.N., Jaffa A.A., Margolius H.S., Mayfield R.K. Renal kallikrein and the hemodynamic abnormalities of the diabetic kidney. Diabetes. 39:1990;299-304.
12. Jaffa A.A., Rust P.F., Mayfield R.K. Kinin: a mediator of diabetes-induced glomerular hyperfiltration. Diabetes. 44:1995;156-160.
13. Lovett D.H., Sterzel R.B., Kashgarian M., Ryan J.L. Proteinase activity produced in vitro by cells of glomerular mesangium. Kidney Int. 23:1983;342-349.
14. Jaffa A.A., Miller D.H., Bailey G.S., Chao J., Margolius H.S., Mayfield R.K. Abnormal regulation of renal kallikrein in experimental diabetes: effects of insulin on prokallikrein synthesis and activation. J. Clin. Invest. 80:1987;1651-1659.
15. Jaffa A.A., Chai K.X., Chao J., Chao L., Mayfield R.K. Effects of diabetes and insulin on expression of kallikrein and rennin genes in the kidney. Kidney Int. 47:1992;789-795.
16. Jaffa A.A., Vio C.P., Velarde V., LeRoith D., Mayfiled R.K. Renal Kallikrein and rennin mRNA levels in diabetes and their induction by insulin and insulin like growth factor I. Diabetes. 46:1997;2040-2056.
17. Vora J.P., Oyama T.T., Thompson M.M., Anderson S. Interactions of the kallikrein-kinin system and renin-angiotensin systems in experimental diabetes. Diabetes. 46:1997;107-112.
18. Tschope C.A., Reinecke A., Seidl U., Yu M., Gavriluk V., Riester U.et al. Functional, biochemical and molecular investigations of renal kallikrein-kinin system in diabetic rats. Am. J. Physiol. 277:1999;H2333-H2340.
19. Haneda M., Araki S., Togawa M., Sugimoto T., Isono M., Kikkawa R. MAPK cascade is activated in glomeruli of dabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes. 46:1997;847-853.
20. Schaeffer H.J., Weber M.J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol. 19:1999;2435-2444.
21. 2-kinin receptors by glucose in vascular smooth muscle cells. Am. J. Physiol. 280:2001;H1537-H1546.
22. Pieper G.M., Riaz-ul-Hag Activation of nuclear factor-kappa B in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J. Cardiovasc. Pharmacol. 30:1997;528-532.
23. Kreisberg J.I., Radnik R.A., Kreisberg S.H. Phosphorylation of cAMP responsive element binding protein after treatment of mesangial cells with high glucose plus TGF-beta or PMA. Kidney Int. 50:1996;805-810.
24. Ni A., Chao L., Chao J. Transcription factor nuclear kB regulates the inducible expression of the human b1 receptor in inflammation. J. Biol. Chem. 273:1998;2784-2791.
25. Ma J., Wang D., Chao L., Chao J. Structure and chromosonal localization of the gene (BDKRB2) encoding bradykinin b2 receptor. Genomics. 23:1994;362-369.
26. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 317:1998;703-713.
27. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.E. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329:1993;1456-1462.